Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02330380 · ClinicalTrials.gov registry record
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
A clinical trial, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- 26
- Enrollment target
NCT02330380 is a clinical trial that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 26 participants.
The verdict
NCT02330380 has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
This is a prospective longitudinal observational pilot study of psoriasis patients on continuous standard-of-care systemic therapeutics to determine the level of change in established (plasma/serum) and investigative (cellular) biomarkers that are associated with increased risk of CVD events. The final endpoint of the proposed study will be a ranking of the examined biomarkers based upon an integrated assessment of biomarker behavior over time. Secondary outcomes will assess changes in coronary artery calcification scoring, PET-MRI, skin biopsies, and clinical improvement.
Interventions
- DRUG Ustekinumab
- DRUG Adalimumab
- DRUG Methotrexate
- DRUG Etanercept
- DRUG Acitretin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-04 |
| Est. Completion | 2016-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02330380
The ClinicalTrials.gov registry entry for NCT02330380 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ustekinumab is the first listed.
NCT02330380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02330380 about?
NCT02330380 is a clinical study titled "Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation". This is a prospective longitudinal observational pilot study of psoriasis patients on continuous standard-of-care systemic therapeutics to determine the level of change in established (plasma/serum) and investigative (cellular) biomarkers that are associated with increased risk of CVD events. The f...
What is the current status of trial NCT02330380?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2013-04. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02330380?
The interventions under investigation include: Ustekinumab (DRUG), Adalimumab (DRUG), Methotrexate (DRUG), Etanercept (DRUG), Acitretin (DRUG).
Who is sponsoring clinical trial NCT02330380?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.